BIOGEN INC (1BIIB.MI) Stock Overview
Europe - BIT:1BIIB - US09062X1037 - Common Stock
1BIIB.MI Key Statistics, Chart & Performance
The current stock price of 1BIIB.MI is 124 EUR. In the past month the price decreased by -39.16%.
1BIIB.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.47 | 346.25B | ||
| 1ABBV.MI | ABBVIE INC | 21.34 | 344.13B | ||
| AMG.DE | AMGEN INC | 13.4 | 135.69B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.54 | 128.80B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 25.27 | 94.65B | ||
| 1REGN.MI | REGENERON PHARMACEUTICALS | 12.65 | 52.80B | ||
| 1AE.DE | ARGENX SE | 94.23 | 43.22B | ||
| ARGX.BR | ARGENX SE | 94.23 | 43.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.84B | ||
| IDP.DE | BIOGEN INC | 9.39 | 19.01B | ||
| 1NBIX.MI | NEUROCRINE BIOSCIENCES INC | 41.11 | 11.91B | ||
| 0QF.DE | MODERNA INC | N/A | 8.97B |
Related stock screener links
About 1BIIB.MI
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS US
Employees: 7605
Phone: 17814642000
BIOGEN INC / 1BIIB.MI FAQ
What does BIOGEN INC do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
What is the current price of 1BIIB stock?
The current stock price of 1BIIB.MI is 124 EUR. The price decreased by -2.21% in the last trading session.
What is the dividend status of BIOGEN INC?
1BIIB.MI does not pay a dividend.
How is the ChartMill rating for BIOGEN INC?
1BIIB.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists 1BIIB stock?
1BIIB.MI stock is listed on the Euronext Milan exchange.
Should I buy 1BIIB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1BIIB.MI.
What is the ownership structure of BIOGEN INC (1BIIB.MI)?
You can find the ownership structure of BIOGEN INC (1BIIB.MI) on the Ownership tab.
1BIIB.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1BIIB.MI.
1BIIB.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1BIIB.MI. 1BIIB.MI is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
1BIIB.MI Financial Highlights
Over the last trailing twelve months 1BIIB.MI reported a non-GAAP Earnings per Share(EPS) of 13.81. The EPS decreased by -3.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| Debt/Equity | 0.36 |
1BIIB.MI Forecast & Estimates
42 analysts have analysed 1BIIB.MI and the average price target is 146.58 EUR. This implies a price increase of 18.21% is expected in the next year compared to the current price of 124.
For the next year, analysts expect an EPS growth of -1.7% and a revenue growth 0.4% for 1BIIB.MI